HCW Biologics Inc. (HCWB)
Largest Insider Buys in Sector
HCWB Stock Price History Chart
HCWB Stock Performance
About HCW Biologics Inc.
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical …
Insider Activity of HCW Biologics Inc.
Over the last 12 months, insiders at HCW Biologics Inc. have bought $0 and sold $0 worth of HCW Biologics Inc. stock.
On average, over the past 5 years, insiders at HCW Biologics Inc. have bought $2.97M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,800 shares for transaction amount of $3,741 was made by Wong Hing C (Chief Executive Officer) on 2023‑09‑14.
List of Insider Buy and Sell Transactions, HCW Biologics Inc.
| 2023-09-14 | Chief Executive Officer | 1,800 0.0049% | $2.08 | $3,741 | -45.54% | |||
| 2023-09-14 | director | 1,041 0.0028% | $2.05 | $2,139 | -45.54% | |||
| 2023-09-13 | Chief Financial Officer | 5,000 0.0144% | $2.10 | $10,490 | -42.57% | |||
| 2023-09-13 | director | 546 0.0015% | $2.05 | $1,117 | -42.57% | |||
| 2023-09-12 | Chief Financial Officer | 5,000 0.0143% | $2.09 | $10,442 | -42.86% | |||
| 2023-09-12 | director | 500 0.0014% | $2.05 | $1,025 | -42.86% | |||
| 2023-09-11 | Chief Financial Officer | 5,000 0.0145% | $2.05 | $10,273 | -41.11% | |||
| 2023-09-11 | director | 99 0.0003% | $2.05 | $203 | -41.11% | |||
| 2023-09-08 | Chief Financial Officer | 5,000 0.0137% | $2.02 | $10,111 | -42.93% | |||
| 2023-09-08 | director | 1 <0.0001% | $1.90 | $2 | -42.93% | |||
| 2023-09-07 | Chief Financial Officer | 5,000 0.0139% | $1.95 | $9,742 | -40.00% | |||
| 2023-09-07 | director | 63 0.0002% | $1.95 | $123 | -40.00% | |||
| 2023-09-06 | Chief Financial Officer | 5,000 0.0144% | $1.95 | $9,749 | -38.10% | |||
| 2023-09-05 | director | 400 0.0011% | $1.75 | $700 | -40.00% | |||
| 2023-06-09 | Chief Financial Officer | 20,000 0.057% | $2.06 | $41,286 | -21.04% | |||
| 2023-06-08 | Chief Financial Officer | 4,696 0.0135% | $2.21 | $10,388 | -25.58% | |||
| 2023-06-08 | SVP of Business Development | 10,000 0.028% | $2.16 | $21,574 | -25.58% | |||
| 2023-06-07 | Chief Financial Officer | 20,000 0.0542% | $2.03 | $40,632 | -23.37% | |||
| 2023-06-06 | Chief Financial Officer | 19,062 0.0524% | $1.82 | $34,779 | -13.51% | |||
| 2023-06-05 | Chief Financial Officer | 20,000 0.054% | $1.67 | $33,344 | -6.98% |
Insider Historical Profitability
| Wong Hing C | Chief Executive Officer | 15314868 40.4905% | $0.78 | 14 | 0 | <0.0001% |
| Byam Rebecca | Chief Financial Officer | 573946 1.5174% | $0.78 | 22 | 0 | <0.0001% |
| GARRETT SCOTT T | director | 125000 0.3305% | $0.78 | 1 | 0 | <0.0001% |
| Flowers Lee | SVP of Business Development | 111308 0.2943% | $0.78 | 5 | 0 | <0.0001% |
| Rhode Peter | See Remarks | 46785 0.1237% | $0.78 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Avantax Planning Partners | $314,610.00 | 0.48 | 179,777 | +0.13% | +$413.00 | 0.01 | |
| Hightower Advisors | $316,000.00 | 0.48 | 179,810 | 0% | +$0 | <0.0001 | |
| Geode Capital Management | $291,132.00 | 0.46 | 174,284 | +29.64% | +$66,563.93 | <0.0001 | |
| Cresset Asset Management Llc | $230,983.00 | 0.35 | 131,990 | 0% | +$0 | <0.01 | |
| Bridgeway Capital Management | $141,449.00 | 0.22 | 84,700 | 0% | +$0 | <0.01 |